Aristada is a prescription medication used to treat schizophrenia in adults [1]. It is administered via intramuscular injection [1]. The HCPCS code for Aristada is J1303 [2].
What is Aristada and how does it work?
Aristada (aripiprazole lauroxil) is an extended-release injectable antipsychotic medication used for the maintenance treatment of schizophrenia [1]. It is a prodrug of aripiprazole, meaning it is converted into the active drug, aripiprazole, in the body [3]. Aripiprazole works by affecting dopamine and serotonin pathways in the brain [3].
How is Aristada administered?
Aristada is given as an intramuscular injection by a healthcare professional [1]. It is available in different strengths and is typically administered on a monthly or every two-month schedule, depending on the prescribed regimen [1].
What is the J-code for Aristada?
The Healthcare Common Procedure Coding System (HCPCS) code for Aristada is J1303 [2]. This code is used for billing and reimbursement purposes by healthcare providers to Medicare and other insurers [2].
What does the J-code J1303 represent?
J1303 represents one milligram of aripiprazole lauroxil extended-release injectable suspension [2]. This code allows for accurate payment for the drug based on the dosage administered [2].
Are there other forms or brand names for Aristada?
Aristada has been discontinued by its manufacturer [4]. However, its active ingredient, aripiprazole, is available under various brand names and as a generic medication in different formulations, including oral tablets and other injectable forms [3].
When does Aristada's patent expire?
Information on specific patent expiration dates for Aristada is proprietary and subject to change through legal challenges or new patent filings [5]. DrugPatentWatch.com tracks patent information for pharmaceutical products, which can be a resource for determining patent exclusivity [5].
What are the potential side effects of Aristada?
Common side effects of Aristada can include injection site reactions, insomnia, headache, and increased weight [1]. More serious side effects may occur, and patients should discuss these with their healthcare provider [1].
How does Aristada compare to other long-acting injectables for schizophrenia?
Aristada was an option for long-acting injectable treatment for schizophrenia, offering a different dosing schedule and pharmacokinetic profile compared to other available long-acting antipsychotics [3]. The choice of injectable medication depends on individual patient needs, tolerability, and physician recommendation [3].